Motus GI Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update
Related Documents
Q2 2021
Quarter Ended Jun 30, 2021
Motus GI Reports Second Quarter 2021 Financial Results and Provides Corporate Update
- Reported a 95% revenue increase versus Q1 2021; the fourth consecutive quarter of revenue growth
- Received FDA clearance for Pure-Vu sleeve for Upper GI endoscopies and initiated pilot patient cases
- Announced enrollment in EU clinical study assessing the Pure-Vu® System for outpatient CRC screening
- Secured minimally dilutive $12.0 million credit financing to support commercial sales growth
FORT LAUDERDALE, Fla., Aug. 12, 2021 (GLOBE NEWSWIRE) -- Motus GI Holdings, Inc., (NASDAQ: MOTS) ("Motus GI" or the "Company"), a medical technology company providing endoscopy solutions that improve clinical outcomes and enhance the cost-efficiency associated with the diagnosis and management of gastrointestinal conditions, today reported its financial results for the second quarter and six months ended June 30, 2021, and provided a corporate update.
“Our team continues to execute our commercial strategy, as we build steady momentum by converting targeted U.S. hospitals into active Pure-Vu customers,” commented Tim Moran, Chief Executive Officer at Motus GI. “The second quarter represented our fourth consecutive quarter of incremental revenue growth and a ~95% increase in revenue compared to the first quarter of 2021. This trend is being driven in part by Pure-Vu disposable sleeve sales as existing customers increase their usage of the Pure-Vu System and we sign additional customers to volume commitment agreements.”
“In addition to our commercial progress, we are executing against our plans to expand our Pure-Vu portfolio through innovative new product launches, seeking to gain reimbursement coverage, generating additional compelling clinical data, and advancing discussions with several potential strategic partners. We believe each of these catalysts have the potential to enhance the enterprise value of the Company,” continued Mr. Moran. “We’ve now commenced initial pilot patient cases of our disposable sleeve for upper GI procedures, which allows for expanded utility of the Pure-Vu System in the GI Lab. This launch is synergistic to the work we are already doing in colonoscopy and will feed right into the upcoming introduction of our third generation Pure-Vu System, which offers even greater ease of use and will support both upper and lower GI procedures. We believe this is an exciting period in our company’s history, and we look forward to keeping everyone updated on our progress.”
Second Quarter and Recent Business Highlights
- Revenue Growth - Reported the fourth sequential quarter of sales growth, which is largely attributable to increased disposable sleeve sales for procedures using the Pure-Vu System.
- Increased Number of Customer Agreements – The Company now has five medical centers signed to 12-month committed volume agreements for disposable sleeve purchase orders, which provide for recurring revenues. In addition, the Company completed the capital sale of a Pure-Vu® System to Sinai Hospital of Baltimore, a LifeBridge Health center, in the second quarter of 2021. This represents an important initial customer hospital in a large health system.
- Initiated pilot cases in Upper GI Product Market - Commenced initial pilot cases of the Pure-Vu Upper GI product, which is focused on targeted evaluations by existing Pure-Vu accounts currently using the system for colonoscopy. The purpose of these initial series of procedures is to demonstrate clinical utility of the Upper GI product, while also gaining real-world learnings.
-
Inpatient and Outpatient Reimbursement Strategy - Advancing strategy to secure reimbursement for the Pure-Vu System when used for certain inpatient and outpatient colonoscopies.
In March 2021, we presented a request for an ICD-10 code at a Center for Medicare and Medicaid Services (“CMS”) meeting, which is part of our broader strategy to obtain reimbursement for certain inpatient and outpatient procedures where the Pure-Vu System can help facilitate visualization of inadequately prepared colons in high medical need patients. On August 2, 2021, CMS granted the Pure-Vu System a permanent ICD-10 code which will commence on October 1, 2021. The Pure-Vu System was not selected for the fast-track new technology add-on payment for inpatient procedures. However, the Company does not believe it faces reimbursement headwinds in the hospital inpatient environment.
- Announced Development of Pure-Vu EVS, 3rd Generation Platform - The development of the ‘Pure-Vu EVS’, the third generation of the Company’s system that will offer continued advancement of the current platform, including enhanced ease-of-use, upper and lower GI capabilities, and a reduced footprint workstation. The Company expects to submit the Pure-Vu EVS System to the FDA for 510K review by the end of 2021.
- Initiated EU Study Exploring Limited Bowel Prep for CRC Screeening - Enrolled the first patients in the European Union feasibility outpatient study evaluating the clinical outcomes in patients with a history of poor bowel preparation using a low volume preparation with limited diet restrictions and the Pure-Vu System.
- Progression of U.S. Study for Lower GI with Limited Bowel Prep - Continuing to successfully enroll patients in the U.S.-based, investigator-initiated clinical study being conducted by a leading U.S. academic medical center to examine using the Pure-Vu System in patients with lower GI bleeding with minimal pre-procedural bowel prep.
- Peer Reviewed Data Published - Announced the publication of data from the REDUCE (“Reliable Endoscopic Diagnosis Utilizing Cleansing Enhancement”) study in the peer-reviewed journal BMC Gastroenterology. As previously announced, among the important findings from the REDUCE study is that the Pure-Vu System showed a 97% clinical success rate. Also, during the second quarter, the Company announced the peer-reviewed publication of new data from a Company sponsored cost effectiveness and resource allocation analysis of the Pure-Vu System® on the outcomes of cost, quality of life, and aversion of colorectal cancers, as compared to the current standard of care for outpatient colonoscopy. This data was published in the journal Cost Effectiveness and Resource Allocation.
- Enhanced Financial Stability – Secured an expanded $12 million credit financing to support the Company’s commercial sales growth and advancement of its additional value creation drivers, which also replaces the previous $8.0 million term loan agreement with Silicon Valley Bank and removes the existing $10.0 million minimum cash balance liquidity covenant.
- Recent Board Appointment - Appointed seasoned biotech industry executive, Sonja Nelson, CPA, to the Board of Directors and as Chair of the Audit Committee, who will be a valuable new resource for the management team as the Company continues to ramp up its commercial growth strategy with a goal of building long-term shareholder value.
Financial Results for the Quarter Ended June 30, 2021
The Company reported revenue of approximately $100,000 for the second quarter of 2021, compared to approximately $1,000 for the same period last year, and approximately $51,000 for the first quarter of 2021.
For the three months ended June 30, 2021, we reported a net loss of $4.7 million, or $0.10 per basic and diluted share, compared to a net loss of $4.4 million, or $0.15 per basic and diluted share, for the same period last year.
During the second quarter 2021, net cash used in operating activities and for the purchase of fixed assets was $3.2 million as compared to $4.3 million for the same period of 2020, a reduction of approximately 26% year-over-year.
The Company reported $26.4 million in cash and cash equivalents as of June 30, 2021. This balance includes $8 million from our 2019 term loan agreement with Silicon Valley Bank. In July 2021, we refinanced this loan and increased our credit facility by 50% up to $12 million through the execution of a new loan agreement with Kreos Capital. Our current cash balance allows us to continue executing on our value creation drivers and is expected to meet our overall anticipated cash needs through 2022.
Conference Call:
The Motus GI management team has scheduled a conference call for today, August 12th, at 4:30 p.m. ET to discuss these results. To access the conference call, investors are invited to dial (877) 407-0792 (U.S. and Canada) or (201) 689-8263 (International). The conference ID number is 13720949. A live audio webcast can be accessed by visiting the investor relations section of the Company’s website, www.motusgi.com or http://public.viavid.com/index.php?id=145456. A replay of the webcast will be archived on the Motus GI website for 90 days following the event.
About Motus GI
Motus GI Holdings, Inc. is a medical technology company, with subsidiaries in the U.S. and Israel, providing endoscopy solutions that improve clinical outcomes and enhance the cost-efficiency associated with the diagnosis and management of gastrointestinal conditions.
For more information, visit www.motusgi.com and connect with the Company on Twitter, LinkedIn and Facebook.
Forward-Looking Statements
This press release contains certain forward-looking statements. Forward-looking statements are based on the Company's current expectations and assumptions. The Private Securities Litigation Reform Act of 1995 provides a safe harbor for forward-looking statements. These statements may be identified by the use of forward-looking expressions, including, but not limited to, "expect," "anticipate," "intend," "plan," "believe," "estimate," "potential," "predict," "project," "should," "would" and similar expressions and the negatives of those terms, including without limitation, risks related to the Company’s cost reduction plan, the cost savings and the cash expenses related to the implementation of the plan, risks related to the continued impact of the COVID-19 pandemic, risks inherent in the development and commercialization of potential products, uncertainty in the timing and results of clinical trials or regulatory approvals, maintenance of intellectual property rights or other risks discussed in the Company’s Form 10-K filed on March 16, 2021, and its other filings with the Securities and Exchange Commission. Prospective investors are cautioned not to place undue reliance on such forward-looking statements, which speak only as of the date hereof. The Company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise.
Investor Contact:
Bob Yedid
LifeSci Advisors
(646) 597-6989
bob@lifesciadvisors.com
Motus GI Holdings, Inc. and Subsidiaries
Condensed Consolidated Balance Sheets
(in thousands, except share and per share amounts)
| June 30, | December 31, | |||||||
| 2021 | 2020 | |||||||
| (unaudited) | ||||||||
| Assets | ||||||||
| Current assets: | ||||||||
| Cash and cash equivalents | $ | 26,379 | $ | 20,819 | ||||
| Accounts receivable | 73 | 35 | ||||||
| Inventory | 706 | 805 | ||||||
| Prepaid expenses and other current assets | 859 | 448 | ||||||
| Total current assets | 28,017 | 22,107 | ||||||
| Fixed assets, net | 1,451 | 1,178 | ||||||
| Right-of-use assets | 712 | 766 | ||||||
| Other non-current assets | 13 | 13 | ||||||
| Total assets | $ | 30,193 | $ | 24,064 | ||||
| Liabilities and Shareholders’ Equity | ||||||||
| Current liabilities: | ||||||||
| Accounts payable and accrued expenses | $ | 2,150 | $ | 2,333 | ||||
| Operating lease liabilities – current | 261 | 238 | ||||||
| Other current liabilities | 7 | 60 | ||||||
| Term debt, net of debt discount of $17 and $21, respectively | 7,983 | 7,979 | ||||||
| Total current liabilities | 10,401 | 10,610 | ||||||
| Contingent royalty obligation | 1,734 | 1,617 | ||||||
| Operating lease liabilities - non-current | 467 | 547 | ||||||
| Total liabilities | 12,602 | 12,774 | ||||||
| Commitments and contingent liabilities (Note 9) | ||||||||
| Shareholders’ equity | ||||||||
| Preferred Stock $0.0001 par value; 10,000,000 shares authorized; zero shares issued and outstanding | - | - | ||||||
| Common Stock $0.0001 par value; 115,000,000 shares authorized; 48,241,188 and 32,272,309 shares issued and outstanding as of June 30, 2021 and December 31, 2020, respectively | 5 | 3 | ||||||
| Additional paid-in capital | 130,698 | 115,008 | ||||||
| Accumulated deficit | (113,112 | ) | (103,721 | ) | ||||
| Total shareholders’ equity | 17,591 | 11,290 | ||||||
| Total liabilities and shareholders’ equity | $ | 30,193 | $ | 24,064 | ||||
Motus GI Holdings, Inc. and Subsidiaries
Condensed Consolidated Statements of Comprehensive Loss
(unaudited, in thousands, except share and per share amounts)
|
Three Months Ended June 30, |
Six Months Ended June 30, |
|||||||||||||||
| 2021 | 2020 | 2021 | 2020 | |||||||||||||
| Revenue | $ | 100 | $ | 1 | $ | 151 | $ | 29 | ||||||||
| Operating expenses: | ||||||||||||||||
| Cost of revenue - sales | 42 | 10 | 70 | 40 | ||||||||||||
| Research and development | 1,508 | 1,264 | 2,853 | 3,199 | ||||||||||||
| Sales and marketing | 795 | 582 | 1,471 | 2,445 | ||||||||||||
| General and administrative | 2,345 | 2,365 | 4,789 | 5,277 | ||||||||||||
| Total costs and expenses | 4,690 | 4,221 | 9,183 | 10,961 | ||||||||||||
| Operating loss | (4,590 | ) | (4,220 | ) | (9,032 | ) | (10,932 | ) | ||||||||
| Gain (loss) on change in estimated fair value of contingent royalty obligation | (37 | ) | (76 | ) | (117 | ) | 245 | |||||||||
| Finance expense, net | (117 | ) | (119 | ) | (234 | ) | (231 | ) | ||||||||
| Foreign currency gain (loss) | 2 | 5 | (8 | ) | (3 | ) | ||||||||||
| Net loss | (4,742 | ) | (4,410 | ) | (9,391 | ) | (10,921 | ) | ||||||||
| Deemed dividends from warrant issuance | - | - | (6,145 | ) | - | |||||||||||
| Net loss attributable to common shareholders | $ | (4,742 | ) | $ | (4,410 | ) | $ | (15,536 | ) | $ | (10,921 | ) | ||||
| Basic and diluted loss per common share: | ||||||||||||||||
| Net loss | $ | (0.10 | ) | $ | (0.15 | ) | $ | (0.21 | ) | $ | (0.38 | ) | ||||
| Net loss attributable to common shareholders | $ | (0.10 | ) | $ | (0.15 | ) | $ | (0.34 | ) | $ | (0.38 | ) | ||||
| Weighted average number of common shares outstanding, basic and diluted | 47,732,674 | 28,846,881 | 45,493,776 | 28,832,296 | ||||||||||||
Released August 12, 2021